Meiring, Joyce C. M. http://orcid.org/0000-0001-9166-5363
Bryce, Nicole S. http://orcid.org/0000-0001-9799-7393
Niño, Jorge Luis Galeano
Gabriel, Antje
Tay, Szun S.
Hardeman, Edna C.
Biro, Maté http://orcid.org/0000-0001-5852-3726
Gunning, Peter W. http://orcid.org/0000-0003-0833-3128
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1100202, APP1079866, APP1100202)
Department of Education and Training | Australian Research Council (DP16010162)
The Kid's Cancer Project
European Molecular Biology Laboratory (EMBL) Australia
Article History
Received: 11 December 2018
Accepted: 11 April 2019
First Online: 24 April 2019
Competing Interests
: P.W.G. and E.C.H.are directors and shareholders of TroBio Therapeutics, a company that is commercializing anti-tropomyosin drugs for the treatment of cancer and their labs receive funding from TroBio to evaluate anti-tropomyosin drug candidates. J.C.M.M., N.S.B., J.L.G.N., S.S.T. and M.B. declare no financial competing interests. All authors declare no non-financial competing interests.